We conducted a systematic review and meta-analysis of the current prophylactic interventions and their effectiveness in mitigating the risk of hereditary breast and ovarian cancers among carriers of BRCA1 or BRCA2 mutations. This evidence concerns the gene BRCA2 and ovarian carcinoma.